In vitro and preclinical in vivo data suggest that leptin acts as a mitogenic agent to promote prostate, breast, and ovarian cancer cell growth and/or enhances cancer angiogenesis and migration [32]–[34]. Here, LEP is linked to ovarian carcinoma.